In observational analyses, this therapeutic approach is associated with more favorable outcomes in patients with a maximum tumor diameter of ≤ 3 cm, AFP, or in BCLC stage B. This approach provides a new local treatment option for HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.